<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Canakinumab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Canakinumab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Canakinumab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11542" href="/d/html/11542.html" rel="external">see "Canakinumab: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="17066" href="/d/html/17066.html" rel="external">see "Canakinumab: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F7874024"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ilaris</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869130"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Ilaris</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F7879808"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Interleukin-1 Beta Inhibitor;</li>
<li>
                        Interleukin-1 Inhibitor;</li>
<li>
                        Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F7883738"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="113bffe4-1a35-4428-b201-35c2c97b4a89">Cryopyrin-associated periodic syndromes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cryopyrin-associated periodic syndromes (CAPS):</b>
<b>SUBQ:</b> 150 mg (&gt;40 kg) or 2 mg/kg (15 to 40 kg) every 8 weeks; in clinical trials, dosage adjustments up to 600 mg (&gt;40 kg) or 8 mg/kg (≤40 kg) and/or increased dosing frequency were allowed for residual symptoms (Kuemmerle-Deschner 2011). For inadequate response, a dose titration schedule of 150 mg or 2 mg/kg every 7 days up to a maximum dose of 600 mg or 8 mg/kg (15 to 40 kg) has been recommended (Ilaris Canadian product monograph).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f63c7497-6ee5-4cb2-9cc5-95a73d037cf4">Familial Mediterranean fever, hyperimmunoglobulin D syndrome/mevalonate kinase deficiency, tumor necrosis factor receptor associated periodic syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Familial Mediterranean fever (FMF), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), tumor necrosis factor receptor associated periodic syndrome (TRAPS): SUBQ:</b>
<b>Initial:</b> 150 mg (&gt;40 kg) or 2 mg/kg (≤40 kg) every 4 weeks; may increase to 300 mg (&gt;40 kg) or 4 mg/kg (≤40 kg) every 4 weeks if response to the initial dose was not adequate or if an early supplemental dose was used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29768139','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29768139','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Early inadequate response</i>
<i>(off-label dosing)</i>: SUBQ:</b> If inadequate response to initial dose occurs between days 8 and 28 (eg, baseline flare persists), an additional 150 mg (&gt;40 kg) or 2 mg/kg (≤40 kg) may be given (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29768139']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29768139'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="95db442d-efd8-4b89-a10a-1e5c87357c02">Gout, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gout, treatment (acute flares) (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve use for patients who have frequent flares <b>and</b> in whom first-line therapies are ineffective, contraindicated, or not tolerated (ACR [FitzGerald 2020]; EULAR [Richette 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> 150 mg as a single dose; repeat doses may be administered at intervals of ≥12 weeks (EULAR [Richette 2017]; Schlesinger 2012; manufacturer’s labeling).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6408b952-3837-492c-83f5-84d78a145712">Still disease, adult onset</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Still disease, adult onset:</b>
<b>SUBQ:</b> 4 mg/kg every 4 weeks (maximum: 300 mg/dose).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991945"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50989213"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F7883739"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F7883737"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="17066" href="/d/html/17066.html" rel="external">see "Canakinumab: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="113bffe4-1a35-4428-b201-35c2c97b4a89">Cryopyrin-associated periodic syndromes</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cryopyrin-associated periodic syndromes (CAPS):</b> Patient syndromes included in trials were: Familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), chronic infantile neurological cutaneous articular syndrome/neonatal onset multisystemic inflammatory disease (CINCA/NOMID), and familial cold urticaria (FCU); data has shown that pediatric patients require higher doses than adults (Kuemmerle-Deschner 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Manufacturer's labeling:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥4 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">15 to 40 kg: SUBQ: Initial: 2 mg/kg/dose every 8 weeks; may increase to 3 mg/kg/dose if response inadequate.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;40 kg: SUBQ: 150 mg/dose every 8 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Alternate dosing:</i> Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to &lt;4 years and weighing ≥7.5 kg: SUBQ: 4 mg/kg/dose every 8 weeks; if no response after 7 days, may repeat 4 mg/kg dose; if response achieved then may continue patient on intensified maintenance of 8 mg/kg/dose every 8 weeks (Ilaris prescribing information, United Kingdom 2017).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥4 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">7.5 to &lt;15 kg: SUBQ: 4 mg/kg/dose every 8 weeks. If no response after 7 days, may administered a second 4 mg/kg/dose; if full treatment response achieved then may continue patient on intensified maintenance of 8 mg/kg/dose every 8 weeks (Ilaris prescribing information, United Kingdom 2017).</p>
<p style="text-indent:-2em;margin-left:8em;">15 to 40 kg: SUBQ: 2 mg/kg/dose every 8 weeks. If response not satisfactory after 7 days, may repeat 2 mg/kg dose; if full treatment response achieved then may continue patient on intensified maintenance of 4 mg/kg/dose every 8 weeks. If after 7 days (ie, day 14) a satisfactory response still not achieved, may administer another 4 mg/kg dose; if full treatment response achieved then may continue patient on intensified maintenance of 8 mg/kg/dose every 8 weeks (Ilaris prescribing information, United Kingdom 2017; Kuemmerle-Deschner 2011). Another dose-escalation regimen describes titration in 2 mg/kg/dose increments every 7 days up to a maximum dose of 8 mg/kg/dose (Ilaris prescribing information, Canada 2017).</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;40 kg: SUBQ: 150 mg every 8 weeks. If response not satisfactory after 7 days, may repeat 150 mg/dose; if full treatment response achieved then may continue patient on intensified maintenance of 300 mg every 8 weeks. If after 7 days (ie, day 14) a satisfactory response still not achieved, may administer another 300 mg/dose; if full treatment response achieved then may continue patient on intensified maintenance of 600 mg every 8 weeks (Ilaris prescribing information, United Kingdom 2017; Kuemmerle-Deschner 2011). Another dose-escalation regimen describes titration in 150 mg increments every 7 days up to a maximum dose of 600 mg (Ilaris prescribing information, Canada 2017).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dd2834ea-9693-41ae-856f-f7f4864e097c">Familial Mediterranean fever</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Familial Mediterranean fever (FMF): Note:</b> In trials, canakinumab was used as monotherapy and in combination with daily colchicine.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">7.5 to 40 kg: SUBQ: Initial: 2 mg/kg/dose every 4 weeks; if inadequate response after 7 days may repeat dose (2 mg/kg) and increase maintenance dose to 4 mg/kg/dose every 4 weeks if full treatment response (Ilaris prescribing information, Canada 2017; Ilaris prescribing information, United Kingdom 2017).</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;40 kg: SUBQ: Initial: 150 mg every 4 weeks; if inadequate response after 7 days may repeat dose (150 mg) and increase maintenance dose to 300 mg every 4 weeks if full treatment response (Ilaris prescribing information, Canada 2017; Ilaris prescribing information, United Kingdom 2017).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="25ed5104-2b49-4e5a-b222-7a3482cc18ad">Hyperimmunoglobulin D syndrome/mevalonate kinase deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD): </b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">7.5 to 40 kg: SUBQ: Initial: 2 mg/kg/dose every 4 weeks; if inadequate response after 7 days may repeat dose (2 mg/kg) and increase maintenance dose to 4 mg/kg/dose every 4 weeks if full treatment response (Ilaris prescribing information, Canada 2017; Ilaris prescribing information, United Kingdom 2017).</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;40 kg: SUBQ: Initial: 150 mg every 4 weeks; if inadequate response after 7 days may repeat dose (150 mg) and increase maintenance dose to 300 mg every 4 weeks if full treatment response (Ilaris prescribing information, Canada 2017; Ilaris prescribing information, United Kingdom 2017).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="35d2d51d-1880-43c6-89eb-39ca0b09eb95">Juvenile idiopathic arthritis, systemic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Juvenile idiopathic arthritis, systemic:</b> Children ≥2 years weighing at least 7.5 kg and Adolescents: SUBQ: 4 mg/kg/dose every 4 weeks; maximum dose: 300 mg/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b5d8ee11-fd3a-42f7-bbe2-9632299318cb">Tumor necrosis factor receptor associated periodic syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tumor necrosis factor receptor associated periodic syndrome (TRAPS):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">7.5 to 40 kg: SUBQ: Initial: 2 mg/kg/dose every 4 weeks; if inadequate response after 7 days may repeat dose (2 mg/kg) and increase maintenance dose to 4 mg/kg/dose every 4 weeks if full treatment response (Ilaris prescribing information, Canada 2017; Ilaris prescribing information, United Kingdom 2017).</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;40 kg: SUBQ: Initial: 150 mg every 4 weeks; if inadequate response after 7 days may repeat dose (150 mg) and increase maintenance dose to 300 mg every 4 weeks if full treatment response (Ilaris prescribing information, Canada 2017; Ilaris prescribing information, United Kingdom 2017).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51083857"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥2 years and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; has not been studied.</p></div>
<div class="block dohp drugH1Div" id="F51083858"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥2 years and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; has not been studied.</p></div>
<div class="block adr drugH1Div" id="F7883696"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in children, adolescents, and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased uric acid (gout flares: 44%), weight gain (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (20%), gastroenteritis (3% to 11%), nausea (14%), upper abdominal pain (7% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia (16%), thrombocytopenia (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (including upper respiratory tract infection, urinary tract infection, and viral upper respiratory tract infection: ≤55%; serious infection: 2% to 5%), influenza (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (1% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (14%), vertigo (9% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Musculoskeletal pain (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (11%), nasopharyngitis (11% to 34%), pharyngitis (3% to 11%), rhinitis (5% to 17%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum calcium (8%) (Lachmann 2009), hypertriglyceridemia (3% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Proteinuria (8%) (Lachmann 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia (7%) (Lachmann 2009), leukopenia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (≤4%), increased serum aspartate aminotransferase (≤4%), increased serum bilirubin (7%) (Lachmann 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (non-neutralizing: 1% to 4%; neutralizing: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Decreased creatinine clearance (8%) (Lachmann 2009)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Opportunistic infection</p></div>
<div class="block coi drugH1Div" id="F7883693"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to canakinumab or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Active, severe infections</p></div>
<div class="block war drugH1Div" id="F7883694"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: A decrease in WBC, neutrophils, and platelets was observed in clinical trials; some changes were transient and/or mild (eg, thrombocytopenia). One case of neutropenia (ANC &lt;1,500/mm<sup>3</sup>) was reported; monitor blood counts as indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions (excluding anaphylactic reactions) have been reported with use; symptoms may be similar to those that are disease related. Discontinue therapy and initiate appropriate therapy if severe hypersensitivity occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: Caution should be exercised when considering use in patients with a history of new/recurrent infections, with conditions that predispose them to infections, or with latent or localized infections. Patients who develop a new infection while undergoing treatment should be monitored closely. If a patient develops a serious infection, therapy should be discontinued. Therapy should not be initiated in patients with active or chronic infections.</p>
<p style="text-indent:-2em;margin-left:4em;">• Macrophage activation syndrome: Macrophage activation syndrome (MAS) may develop in patients with Still disease and should be treated aggressively. Infection or worsening Still disease may be triggers for MAS.</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancy: Use may impair defenses against malignancies; impact on the development and course of malignancies is not fully defined.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tuberculosis: Avoid use in patients with tuberculosis (TB) disease (active TB). Patients should be evaluated for TB infection (latent TB) with a tuberculin skin test prior to starting therapy. Treat TB infection prior to initiating canakinumab therapy. During and following treatment, monitor for signs/symptoms of TB disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: All patients should be brought up to date with all immunizations including pneumococcal and influenza vaccines before initiating therapy. Live vaccines should not be given concurrently; no data available on either the efficacy or on the risks concerning secondary transmission of infection by live vaccines in patients receiving therapy. Administration of inactivated (killed) vaccines while on therapy may not be effective.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878733"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Reactivation of TB has been reported in pediatric patients receiving biologic response modifiers (infliximab and etanercept); prior to therapy, patients with no TB risk factors should be screened for latent TB infection (LTBI) with an age appropriate test (ie, &lt;5 years of age: tuberculin skin test, and ≥5 years of age: IGRA [interferon gamma release assay]); if any TB risk factors are present or symptoms, both LTBI screening tests should be performed (AAP [Davies 2016])</p>
<p style="text-indent:0em;margin-top:2em;">Influenza reported in 17% of patients during clinical trials. Vertigo has been reported exclusively in patients with MWS (9% to 14%); events appear self-resolving with continued therapy. Infection reported more frequently in children than adults (Kuemmerle-Deschner 2011) for both CAPS and JIA. Treatment for CAPS has been associated with higher incidence of reported adverse reactions including diarrhea (20%), nasopharyngitis (34%), and rhinitis (17%).</p></div>
<div class="block foc drugH1Div" id="F9512584"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ilaris: 150 mg/mL (1 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F7884596"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322118"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ilaris Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg/mL (per mL): $21,806.20</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869131"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ilaris: 150 mg/mL (1 mL) [contains polysorbate 80]</p></div>
<div class="block adm drugH1Div" id="F7883740"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>SUBQ:</b> For subcutaneous injection only by a health care provider. Do not shake solution. Do not inject into scar tissue.</p></div>
<div class="block admp drugH1Div" id="F52614340"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">SubQ: Do not shake; administer subcutaneously at a concentration of 150 mg/mL by a health care provider; avoid sites with scar tissue</p></div>
<div class="block meg drugH1Div" id="F20403141"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F125319s107lbl.pdf%23page%3D24&amp;token=tC66636W7G%2B8COmyoHJXKj%2F3SaI6UsTpn9t1Icmp95JDzknIMT4JUoFDfG%2FDm0aGerxOi7O%2BSzP9d%2BlKkKkv45Be7k5YBhpCU4ypEAd7MRwRraqO3c8PeXhIaMPppoE7&amp;TOPIC_ID=8906" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125319s107lbl.pdf#page=24</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F7879810"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Gout, treatment, acute flares:</b> Treatment of gout flares in adults in whom nonsteroidal anti-inflammatory drugs and colchicine are contraindicated, not tolerated, or do not provide an adequate response, and in whom repeated corticosteroid use is not appropriate.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Periodic fever syndromes:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Cryopyrin-associated periodic syndromes:</b> Treatment of cryopyrin-associated periodic syndromes (CAPS) in adults and children 4 years and older, including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS). <b>Note:</b> Has also been studied in Neonatal-onset multisystem inflammatory disease (Ilaris Canadian product monograph; Sibley 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Familial Mediterranean fever:</b> Treatment of familial Mediterranean fever in adult and pediatric patients.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD): </b>Treatment of hyperimmunoglobulin D (Hyper-IgD) Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Tumor necrosis factor (TNF) receptor associated periodic syndrome:</b> Treatment of TNF receptor associated periodic syndrome (TRAPS) in adult and pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Still disease, adult onset:</b> Treatment of active adult-onset Still disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Systemic juvenile idiopathic arthritis:</b> Treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years and older.</p></div>
<div class="block mst drugH1Div" id="F59034272"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:2em;">Ilaris may be confused with Ilumya</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298949"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F7899286"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-TNF Agents: May enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Interleukin-1 Inhibitors: May enhance the adverse/toxic effect of Canakinumab.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Interleukin-1 Receptor Antagonist: May enhance the adverse/toxic effect of Canakinumab.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54504885"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Fertility may be decreased in males and females with inflammatory diseases such as familial Mediterranean fever. Based on case reports, treatment with canakinumab may improve fertility (Babaoglu 2020; Youngstein 2017).</p></div>
<div class="block pri drugH1Div" id="F7883689"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Canakinumab crosses the placenta; newborn concentrations may be greater than maternal serum concentrations at delivery (Bosshard 2021; Egawa 2017; Weber 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Canakinumab is a recombinant IgG monoclonal antibody; IgG is known to cross the placenta in a linear fashion as pregnancy progresses; potential fetal exposure is likely to be greater during the second and third trimesters.</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data related to the use of canakinumab in pregnancy are limited (Babaoglu 2020; Brien 2021; Dernoncourt 2023; Egawa 2017; İlgen 2022; Youngstein 2017). Other agents are currently preferred for the treatment of adult-onset Still disease (Jamilloux 2014) or familial Mediterranean fever (EULAR [Ozen 2016]) in pregnant patients.</p></div>
<div class="block brc drugH1Div" id="F20607144"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Canakinumab is present in breast milk (Bosshard 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of canakinumab in breast milk are available from a case report:</p>
<p style="text-indent:-2em;margin-left:4em;">• Canakinumab 150 mg was administered prior to pregnancy, during pregnancy (6 and 20 weeks' gestation), then 10 days, 16 weeks, and 32 weeks postpartum to a patient treated for Muckle-Wells syndrome. Breast milk was sampled on days 1 through 9 and day 13 after the first postpartum dose. The maximum breast milk concentration (0.023 mcg/mL) occurred 8 days after the maternal dose. Although canakinumab was present in the umbilical cord at delivery, it was not detected in the serum of the breastfed infant when sampled at 26 weeks postpartum, 10 weeks following a maternal dose. The authors of the study calculated the relative infant dose (RID) of canakinumab via breast milk to be 0.03% to 0.16% of the weight-adjusted maternal dose. Normal development was observed in the infant followed for 2 years (Bosshard 2021). In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:4em;">• Canakinumab was not detectable (&lt;0.5 mcg/mL) in the breast milk of a patient treated for systemic juvenile idiopathic arthritis. The patient was administered canakinumab 150 mg every 4 weeks prior to conception until delivery. Breast milk was sampled 14 days after the last injection (postpartum day 4) (Weber 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• No serious infections and no abnormal development were reported in 4 breastfed infants following maternal use of canakinumab (complete details of exposure not presented) (Youngstein 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F7883742"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential, C-reactive protein (CRP), serum amyloid A protein A (SAA); signs of infection; latent TB screening (prior to initiating therapy).</p>
<p style="text-indent:0em;margin-top:2em;">Eye examinations for patients with CAPS (Caorsi 2013) and symptoms of disease for patients with CAPS or SJIA (Caorsi 2013; Lachmann 2009; Ruperto 2012) were also monitored in clinical trials.</p></div>
<div class="block pha drugH1Div" id="F7883719"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Canakinumab reduces inflammation by binding to interleukin-1 beta (IL-1beta) (no binding to IL-1 alpha  or IL-1 receptor antagonist [IL-1ra]) and preventing interaction with cell surface receptors. Cryopyrin-associated periodic syndromes (CAPS) refers to rare genetic syndromes caused by mutations in the nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3 (NLRP-3) gene or the cold-induced autoinflammatory syndrome-1 (CIAS1) gene. Cryopyrin, a protein encoded by this gene, regulates IL-1beta activation. Deficiency of cryopyrin results in excessive inflammation.</p></div>
<div class="block phk drugH1Div" id="F7883721"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Maximum effect: Within 8 days CRP and serum amyloid normalization.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: Children: 0.097 L/kg (3.2 L in 33 kg); Adults: CAPS: 0.086 L/kg (6.01 L in 70 kg); FMF, HIDS/MKD, TRAPS: 0.09 L/kg (6.34 L in 70 kg); Gout flares: 0.085 L/kg (7.9 L in 93 kg).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Binds to serum IL-1 beta.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Subcutaneous: 66%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Children ≥4 years: 22.9 to 25.7 days; Adults: 26 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Children ≥4 years: 2 to 7 days; Adults: ~7 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance: Varies according to body weight:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≤40 kg: SJIA: 0.11 L/day in 33 kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;40 kg and Adults: CAPS: 0.174 L/day in 70 kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Children, Adolescents, and Adults: FMF, HIDS/MKD, TRAPS: 0.17 L/day in 70 kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Gout flares: 0.23 L/day in 93 kg.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F12707699"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(CY)</span> <span class="country">Cyprus</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(MT)</span> <span class="country">Malta</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Ilaris</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Arostegui JI, Anton J, Calvo I, et al. Long-term efficacy and safety of canakinumab in active hyper-IgD syndrome (HIDS): results from an open-label study. <i>Pediatric Rheumatology</i>. 2015;13(supp 1):58.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30048391">
<a name="30048391"></a>Babaoglu H, Varan O, Kucuk H, et al. Effectiveness of canakinumab in colchicine- and anakinra-resistant or -intolerant adult familial mediterranean fever patients: a single-center real-life study. <i>J Clin Rheumatol</i>. 2020;26(1):7-13. doi:10.1097/RHU.0000000000000873<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/30048391/pubmed" id="30048391" target="_blank">30048391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33999372">
<a name="33999372"></a>Bosshard N, Zbinden A, Eriksson KK, Förger F. Rituximab and canakinumab use during lactation: no detectable serum levels in breastfed Infants. <i>Rheumatol Ther.</i> 2021;8(2):1043-1048. doi:10.1007/s40744-021-00313-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/33999372/pubmed" id="33999372" target="_blank">33999372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35011965">
<a name="35011965"></a>Brien ME, Gaudreault V, Hughes K, Hayes DJL, Heazell AEP, Girard S. A systematic review of the safety of blocking the IL-1 system in human pregnancy. <i>J Clin Med</i>. 2021;11(1):225. doi:10.3390/jcm11010225<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/35011965/pubmed" id="35011965" target="_blank">35011965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25049046">
<a name="25049046"></a>Brik R, Butbul-Aviel Y, Lubin S, et al. Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study. <i>Arthritis Rheumatol</i>. 2014;66(11):3241-3243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/25049046/pubmed" id="25049046" target="_blank">25049046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23442610">
<a name="23442610"></a>Caorsi R, Lepore L, Zulian F, et al, "The Schedule of Administration of Canakinumab in Cryopyrin Associated Periodic Syndrome is Driven By the Phenotype Severity Rather Than the Age," <i>Arthritis Res Ther</i>, 2013, 15(1):R33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/23442610/pubmed" id="23442610" target="_blank">23442610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27432853">
<a name="27432853"></a>Davies HD, Committee on Infectious Disease. Infectious complications with the use of biologic response modifiers in infants and children. <i>Pediatrics</i>. 2016;138(2):e20161209.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/27432853/pubmed" id="27432853" target="_blank">27432853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29768139">
<a name="29768139"></a>De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. <i>N Engl J Med</i>. 2018;378(20):1908-1919. doi:10.1056/NEJMoa1706314<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/29768139/pubmed" id="29768139" target="_blank">29768139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36401769">
<a name="36401769"></a>Dernoncourt A, Liabeuf S, Bennis Y, et al. Fetal and neonatal adverse drug reactions associated with biologics taken during pregnancy by women with autoimmune diseases: insights from an analysis of the World Health Organization Pharmacovigilance Database (VigiBase<sup>®</sup>). <i>BioDrugs</i>. 2023;37(1):73-87. doi:10.1007/s40259-022-00564-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/36401769/pubmed" id="36401769" target="_blank">36401769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28386702">
<a name="28386702"></a>Egawa M, Imai K, Mori M, Miyasaka N, Kubota T. Placental transfer of canakinumab in a patient with muckle-wells syndrome. <i>J Clin Immunol</i>. 2017;37(4):339-341. doi:10.1007/s10875-017-0389-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/28386702/pubmed" id="28386702" target="_blank">28386702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32391934">
<a name="32391934"></a>FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. <i>Arthritis Care Res (Hoboken).</i> 2020;72(6):744-760. doi:10.1002/acr.24180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/32391934/pubmed" id="32391934" target="_blank">32391934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21339216">
<a name="21339216"></a>Furst DE, Keystone EC, Braun J, et al, "Updated Consensus Statement on Biological Agents for the Treatment of Rheumatic Diseases, 2010," <i>Ann Rheum Dis</i>, 2011, 70(Suppl 1)2-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/21339216/pubmed" id="21339216" target="_blank">21339216</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ilaris (canakinumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ilaris.2">
<a name="Ilaris.2"></a>Ilaris (canakinumab) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; November 2022.</div>
</li>
<li>
<div class="reference">
                  Ilaris powder for injection (canakinumab) [prescribing information]. West Sussex, United Kingdom: Novartis Europharm Limited. February 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35018583">
<a name="35018583"></a>İlgen U, Eyüpoğlu Ş, Yayla ME, Küçükşahin O. Fetal exposure to canakinumab: a report of three pregnancies. <i>Clin Rheumatol.</i> 2022;41(4):1261-1263. doi:10.1007/s10067-022-06060-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/35018583/pubmed" id="35018583" target="_blank">35018583</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>NEJM</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25653531">
<a name="25653531"></a>Jamilloux Y, Gerfaud-Valentin M, Henry T, Sève P. Treatment of adult-onset Still's disease: a review. <i>Ther Clin Risk Manag</i>. 2014;11:33-43. doi:10.2147/TCRM.S64951<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/25653531/pubmed" id="25653531" target="_blank">25653531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22152723">
<a name="22152723"></a>Koné-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, et al, "Canakinumab in CAPS Study Group. Sustained Remission of Symptoms and Improved Health-Related Quality of Life in Patients With Cryopyrin-Associated Periodic Syndrome Treated With Canakinumab: Results of a Double-Blind Placebo-Controlled Randomized Withdrawal Study," <i>Arthritis Res Ther</i>, 2011, 13(6):R202.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/22152723/pubmed" id="22152723" target="_blank">22152723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21859692">
<a name="21859692"></a>Kuemmerle-Deschner JB, Hachulla E, Cartwright R, et al, "Two-Year Results From an Open-Label, Multicentre, Phase III Study Evaluating the Safety and Efficacy of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Across Different Severity Phenotypes," <i>Ann Rheum Dis</i>, 2011, 70(12):2095-102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/21859692/pubmed" id="21859692" target="_blank">21859692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19494217">
<a name="19494217"></a>Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al, “Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome,” <i>N Engl J Med</i>, 2009, 360(23):2416-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/19494217/pubmed" id="19494217" target="_blank">19494217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  NCT 00685373, “Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-Associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease”, Unpublished data. Available at <a href="https://clinicaltrials.gov/ct2/show/NCT00685373?term=NCT+00685373&amp;amp;rank=1" target="_blank">http://clinicaltrials.gov/ct2/show/NCT00685373?term=NCT+00685373&amp;rank=1</a>. Date Accessed: October 29, 2011</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26802180">
<a name="26802180"></a>Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. <i>Ann Rheum Dis</i>. 2016;75(4):644-651. doi:10.1136/annrheumdis-2015-208690<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/26802180/pubmed" id="26802180" target="_blank">26802180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27457514">
<a name="27457514"></a>Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. <i>Ann Rheum Dis</i>. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/27457514/pubmed" id="27457514" target="_blank">27457514</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ruperto N, Brunner H, Horneff G, et al, “Efficacy and Safety of Canakinumab, a Longacting Fully Human Anti-Interleukin-1ß Antibody, in Systemic Juvenile Idiopathic Arthritis With Active Systemic Features: Results From a Phase III Study,”<i> Pediatric Rheumatology</i>, 2011, 9(Suppl 1):021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23252526">
<a name="23252526"></a>Ruperto N, Brunner HI, Quartier P, et al, "Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis," <i>N Engl J Med</i>, 2012, 367(25):2396-406.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/23252526/pubmed" id="23252526" target="_blank">23252526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21953497">
<a name="21953497"></a>Ruperto N, Quartier P, Wulffraat N, et al; Paediatric Rheumatology International Clinical Trials Organisation. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. <i>Arthritis Rheum</i>. 2012;64(2):557-567. doi:10.1002/art.33342<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/21953497/pubmed" id="21953497" target="_blank">21953497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22586173">
<a name="22586173"></a>Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. <i>Ann Rheum Dis</i>. 2012;71(11):1839-1848. doi: 10.1136/annrheumdis-2011-200908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/22586173/pubmed" id="22586173" target="_blank">22586173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24906637">
<a name="24906637"></a>Sibley CH, Chioato A, Felix S, et al. A 24 month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease. <i>Ann Rheum Dis</i>. 2015;74(9):1714-1719.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/24906637/pubmed" id="24906637" target="_blank">24906637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27474763">
<a name="27474763"></a>Torene R, Nirmala N, Obici L, et al. Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome. <i>Ann Rheum Dis</i>. 2017;76(1):303-309.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/27474763/pubmed" id="27474763" target="_blank">27474763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35325056">
<a name="35325056"></a>Weber E, Millet A, Beghin D, et al. Safety of canakinumab during pregnancy: seven new cases. <i>Rheumatology (Oxford).</i> 2022;61(8):e229-e231. doi:10.1093/rheumatology/keac177<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/35325056/pubmed" id="35325056" target="_blank">35325056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28968868">
<a name="28968868"></a>Youngstein T, Hoffmann P, Gül A, et al. International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. <i>Rheumatology (Oxford)</i>. 2017;56(12):2102-2108. doi:10.1093/rheumatology/kex305<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/canakinumab-drug-information/abstract-text/28968868/pubmed" id="28968868" target="_blank">28968868</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8906 Version 251.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
